$HOTH
Hoth Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023086133 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.223M $1.050M
YoY Change -30.98% 21.47%
% of Gross Profit
Research & Development $914.6K $1.246M
YoY Change -37.94% -14.14%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.698M $2.093M
YoY Change -50.37% -22.03%
Operating Profit -$2.093M
YoY Change -22.03%
Interest Expense -$3.670K $10.00K
YoY Change -99.22% -75.47%
% of Operating Profit
Other Income/Expense, Net -$790.00 $6.397K
YoY Change -100.19% -84.08%
Pretax Income -$1.702M -$2.090M
YoY Change -51.06% -20.96%
Income Tax
% Of Pretax Income
Net Earnings -$1.702M -$2.087M
YoY Change -51.06% -21.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$0.39 -$0.75
COMMON SHARES
Basic Shares Outstanding 4.346M shares 3.302M shares
Diluted Shares Outstanding 3.484M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.292M $11.85M
YoY Change 39.99% 27.92%
Cash & Equivalents $9.292M $11.83M
Short-Term Investments $0.00 $24.57K
Other Short-Term Assets $135.4K $200.0K
YoY Change 53.04% 4.48%
Inventory
Prepaid Expenses $200.3K
Receivables
Other Receivables
Total Short-Term Assets $9.428M $12.05M
YoY Change 40.16% 26.78%
LONG-TERM ASSETS
Property, Plant & Equipment $55.17K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.40K $30.00K
YoY Change 13.33% -92.26%
Other Assets $92.57K
YoY Change
Total Long-Term Assets $92.57K $33.00K
YoY Change 180.52% -91.48%
TOTAL ASSETS
Total Short-Term Assets $9.428M $12.05M
Total Long-Term Assets $92.57K $33.00K
Total Assets $9.520M $12.09M
YoY Change 40.85% 22.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $35.59K $707.2K
YoY Change -94.88% -24.03%
Accrued Expenses $643.1K $871.7K
YoY Change -3.69% 1560.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $678.7K $1.579M
YoY Change -51.1% 56.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.33K $0.00
YoY Change -89.47% -100.0%
Total Long-Term Liabilities $26.33K $0.00
YoY Change -89.47% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $678.7K $1.579M
Total Long-Term Liabilities $26.33K $0.00
Total Liabilities $705.0K $1.579M
YoY Change -56.95% 23.02%
SHAREHOLDERS EQUITY
Retained Earnings -$52.94M -$51.24M
YoY Change 17.4% 23.12%
Common Stock $435.00 $435.00
YoY Change 234.62% 237.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.815M $10.51M
YoY Change
Total Liabilities & Shareholders Equity $9.520M $12.09M
YoY Change 40.85% 22.15%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.702M -$2.087M
YoY Change -51.06% -21.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.067M -$1.640M
YoY Change 20.28% -31.34%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.650K 2.410M
YoY Change -105.2%
NET CHANGE
Cash From Operating Activities -3.067M -1.640M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -2.650K 2.410M
Net Change In Cash -3.070M 770.0K
YoY Change 22.47% -132.37%
FREE CASH FLOW
Cash From Operating Activities -$3.067M -$1.640M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.067M -$1.640M
YoY Change 19.92% -31.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1164174 shares
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38803
dei Entity Registrant Name
EntityRegistrantName
Hoth Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1553794
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Rockefeller Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1039
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10020
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
756-2997
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
HOTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4346438 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11828242 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6428611 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24567 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
209320 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
200328 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
88450 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
12053137 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6726381 usd
CY2023Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
33000 usd
CY2022Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
33000 usd
CY2023Q3 us-gaap Assets
Assets
12086137 usd
CY2022Q4 us-gaap Assets
Assets
6759381 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
707185 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
694989 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
871684 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
667742 usd
CY2022Q4 hoth Accrued License Fee Current Portion
AccruedLicenseFeeCurrentPortion
25000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1578869 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1387731 usd
CY2022Q4 hoth Accrued License Fee Non Current Portion
AccruedLicenseFeeNonCurrentPortion
250000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1578869 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1637731 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4346438 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4346438 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1302113 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1302113 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
435 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
130 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61726321 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50198630 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51242237 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45099116 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22749 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22006 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10507268 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5121650 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12086137 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6759381 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1246061 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1451280 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2777865 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3370841 usd
CY2023Q3 hoth Research And Development License Acquired
ResearchAndDevelopmentLicenseAcquired
-271687 usd
CY2022Q3 hoth Research And Development License Acquired
ResearchAndDevelopmentLicenseAcquired
16953 usd
hoth Research And Development License Acquired
ResearchAndDevelopmentLicenseAcquired
-212411 usd
hoth Research And Development License Acquired
ResearchAndDevelopmentLicenseAcquired
94678 usd
CY2023Q3 hoth Compensation And Related Expensesincluding Stockbased Compensation
CompensationAndRelatedExpensesincludingStockbasedCompensation
566139 usd
CY2022Q3 hoth Compensation And Related Expensesincluding Stockbased Compensation
CompensationAndRelatedExpensesincludingStockbasedCompensation
348754 usd
hoth Compensation And Related Expensesincluding Stockbased Compensation
CompensationAndRelatedExpensesincludingStockbasedCompensation
1380179 usd
hoth Compensation And Related Expensesincluding Stockbased Compensation
CompensationAndRelatedExpensesincludingStockbasedCompensation
1821613 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
478614 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
498034 usd
us-gaap Professional Fees
ProfessionalFees
1578872 usd
us-gaap Professional Fees
ProfessionalFees
1508330 usd
CY2023Q3 hoth Rent Expenses
RentExpenses
6752 usd
CY2022Q3 hoth Rent Expenses
RentExpenses
17625 usd
hoth Rent Expenses
RentExpenses
29769 usd
hoth Rent Expenses
RentExpenses
47112 usd
CY2023Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
67101 usd
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
351767 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
440152 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
802080 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2092980 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2684413 usd
us-gaap Operating Expenses
OperatingExpenses
5994426 usd
us-gaap Operating Expenses
OperatingExpenses
7644654 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2092980 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2684413 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5994426 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7644654 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-184753 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-194179 usd
CY2022Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
26572 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-132063 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-22600 usd
CY2023Q3 us-gaap Dividend Income Operating
DividendIncomeOperating
5611 usd
CY2022Q3 us-gaap Dividend Income Operating
DividendIncomeOperating
14202 usd
us-gaap Dividend Income Operating
DividendIncomeOperating
35272 usd
us-gaap Dividend Income Operating
DividendIncomeOperating
59334 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
786 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-592 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
786 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40831 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6397 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40182 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148695 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-248677 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2086583 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2644231 usd
us-gaap Net Income Loss
NetIncomeLoss
-6143121 usd
us-gaap Net Income Loss
NetIncomeLoss
-7893331 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46461 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21485 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
743 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31985 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2040122 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2622746 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6142378 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7861346 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.78
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3483735 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1288481 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3093224 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1164174 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9951162 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
495 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
190265 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2405468 usd
CY2023Q3 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
46461 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2086583 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10507268 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11221771 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12354 usd
CY2022Q3 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
21485 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2644231 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8611379 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5121650 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2355 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
210643 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
11314998 usd
us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
743 usd
us-gaap Net Income Loss
NetIncomeLoss
-6143121 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10507268 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
9882292 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
605330 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1014896 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5985103 usd
us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
31985 usd
us-gaap Net Income Loss
NetIncomeLoss
-7893331 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8611379 usd
us-gaap Net Income Loss
NetIncomeLoss
-6143121 usd
us-gaap Net Income Loss
NetIncomeLoss
-7893331 usd
hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
-25000 usd
hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
51500 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-22600 usd
us-gaap Share Based Compensation
ShareBasedCompensation
210643 usd
us-gaap Share Based Compensation
ShareBasedCompensation
605330 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-194179 usd
us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
-184753 usd
us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
-132063 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
141085 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
105428 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
538115 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
245296 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5375695 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6747791 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
66500 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1235694 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1169194 usd
hoth Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O
ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO
11314998 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5985103 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2355 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11317353 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5985103 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-542027 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9695 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5941658 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
406506 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6428611 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8538270 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11828242 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8935081 usd
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
140000 shares
CY2022Q4 hoth Common Stock Shares Purchase
CommonStockSharesPurchase
1860000 shares
CY2022Q4 hoth Warrants Purchase To Shares
WarrantsPurchaseToShares
2500000 shares
CY2022Q4 hoth Common Stock At Purchase Price
CommonStockAtPurchasePrice
5
CY2022Q4 hoth Aggregate Gross Proceeds
AggregateGrossProceeds
10000000 usd
CY2022Q4 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
5
hoth Warrant Exercisable Term Description
WarrantExercisableTermDescription
The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
549275 shares
CY2023Q3 hoth Common Stock Shares Purchase
CommonStockSharesPurchase
550725 shares
CY2023Q3 hoth Common Stock At Purchase Price
CommonStockAtPurchasePrice
2.629
CY2023Q3 hoth Warrants Purchase To Shares
WarrantsPurchaseToShares
1100000 shares
CY2023Q3 hoth Aggregate Gross Proceeds
AggregateGrossProceeds
2.9 usd
CY2023Q3 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
2.505
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net income (loss), stockholder’s equity or cash flows as previously reported. The reclassifications relate to separating dividend income from gain on marketable securities within the condensed consolidated statements of operations and comprehensive loss.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected.</p>
CY2023Q3 hoth Research And Development Expenses
ResearchAndDevelopmentExpenses
-271687 usd
CY2022Q3 hoth Research And Development Expenses
ResearchAndDevelopmentExpenses
16953 usd
hoth Research And Development Expenses
ResearchAndDevelopmentExpenses
-212411 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
11828242 usd
CY2022 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
6428611 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of credit risk and off-balance sheet risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits at the two financial institutions the Company utilizes for its banking requirements. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company has significant cash balances at financial institutions which, throughout the period, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. The Company’s cash deposits above the FDIC insured amounts totaled $11,173,702 and $5,542,838 as of September 30, 2023 and December 31, 2022, respectively. The Company’s foreign bank accounts are not subject to FDIC insurance. Cash held in the Company’s Australian bank accounts as of September 30, 2023 and December 31, 2022 was $154,540 and $385,771 in U.S. dollars, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
250000 usd
us-gaap Interest Income Federal Funds Sold
InterestIncomeFederalFundsSold
250000 usd
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
11173702 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5542838 usd
hoth Australian Bank Accounts
AustralianBankAccounts
154540 usd
CY2022 hoth Australian Bank Accounts
AustralianBankAccounts
385771 usd
CY2023Q3 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
260000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4386259 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
507527 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4386259 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
507527 shares
hoth Schedule Of Research And Development Expenses For Licenses Acquired
ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired
The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and nine months ended September 30, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended <br/> September 30,</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended<br/> September 30,</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,938</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,953</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,714</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,178</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(281,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(275,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">University of Cincinnati</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,875</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(271,687</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,953</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(212,411</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">94,678</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>
hoth Research And Development Expenses
ResearchAndDevelopmentExpenses
94678 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
30000 usd
us-gaap Costs And Expenses
CostsAndExpenses
30000 usd
CY2023Q3 us-gaap Other Expenses
OtherExpenses
5729 usd
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
24567 usd
CY2023Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
33000 usd
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
209320 usd
CY2022Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
33000 usd
CY2023Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
33000 usd
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
33000 usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
33000 usd
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
33000 usd
CY2022Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
387400 usd
CY2022Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
387400 usd
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
410000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-22600 usd
CY2022Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
387400 usd
CY2022Q4 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
27000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
33000 usd
CY2022 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
33000 usd
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
549275 shares
CY2023Q3 hoth Common Stock Shares Purchase
CommonStockSharesPurchase
550725 shares
CY2023Q3 hoth Warrants Purchase To Shares
WarrantsPurchaseToShares
1100000 shares
CY2023Q3 hoth Aggregate Net Proceeds
AggregateNetProceeds
2400000 usd
CY2021Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
66878 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3384 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.16
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3384 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.16
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
104651 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.8
CY2022Q4 hoth Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
us-gaap Stock Issued During Period Shares Employee Stock Ownership Plan
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
90000 shares
hoth Share Based Compensation By Share Based Payment Weighted Average Exercise Price Employee Options Issued
ShareBasedCompensationByShareBasedPaymentWeightedAverageExercisePriceEmployeeOptionsIssued
2.59
hoth Weighted Average Remaining Contractual Lifein Years Employee Options Issued
WeightedAverageRemainingContractualLifeinYearsEmployeeOptionsIssued
P9Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
25291 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
46.1
hoth Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Lifein Years Options Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualLifeinYearsOptionsExpired
P7Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169360 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.8
hoth Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
169360 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
26.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
0 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190265 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12354 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
210643 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
605330 usd
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
184536 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
188502 usd
CY2023Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Tax Benefit
ShareBasedGoodsAndNonemployeeServicesTransactionTaxBenefit
5729 usd
us-gaap Share Based Goods And Nonemployee Services Transaction Tax Benefit
ShareBasedGoodsAndNonemployeeServicesTransactionTaxBenefit
22141 usd
CY2022Q4 us-gaap Common Unit Issued
CommonUnitIssued
140000 shares
CY2022Q4 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
2500000 shares
CY2022Q4 hoth Purchase Price Per Share
PurchasePricePerShare
5
CY2022Q4 hoth Accompanying Warrant Per Share
AccompanyingWarrantPerShare
0.001
CY2022Q4 hoth Aggregate Gross Proceed Amount
AggregateGrossProceedAmount
10000000 usd
CY2022Q4 hoth Aggregate Net Proceeds
AggregateNetProceeds
9000000 usd
hoth Common Stock Warrant Term Description
CommonStockWarrantTermDescription
Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2023Q1 us-gaap Share Price
SharePrice
6.56
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P30Y
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
5
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.3507 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0394 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
15000000 usd
CY2023Q3 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
591090 usd
CY2023Q3 us-gaap Common Unit Issued
CommonUnitIssued
549275 shares
CY2023Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
550725 shares
CY2023Q3 hoth Purchase Price Per Share
PurchasePricePerShare
2.63
CY2023Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
2.505
CY2023Q3 us-gaap Share Price
SharePrice
1.84
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P30Y
CY2023Q3 hoth Unexercised Warrant
UnexercisedWarrant
55675 shares
hoth Leases Office Spaces
LeasesOfficeSpaces
2500 usd
CY2023Q3 us-gaap Payments For Rent
PaymentsForRent
6752 usd
CY2022Q3 us-gaap Payments For Rent
PaymentsForRent
17625 usd
us-gaap Payments For Rent
PaymentsForRent
29769 usd
us-gaap Payments For Rent
PaymentsForRent
47112 usd
CY2023Q3 hoth Accrued License Fee Current Portion
AccruedLicenseFeeCurrentPortion
usd
CY2023Q3 hoth Accrued License Fee Non Current Portion
AccruedLicenseFeeNonCurrentPortion
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2023Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
usd
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2022Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.78
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1288481 shares
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
hoth Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O
ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2022Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
hoth Sharebased Compensation Arrangement By Sharebased Payment Intrinsic Value Employee Options Issued
SharebasedCompensationArrangementBySharebasedPaymentIntrinsicValueEmployeeOptionsIssued
usd
hoth I Share Based Compensation Arrangement By Share Based Paymentntrinsic Value Options Expired
IShareBasedCompensationArrangementByShareBasedPaymentntrinsicValueOptionsExpired
usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001711786

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001213900-23-086133-index-headers.html Edgar Link pending
0001213900-23-086133-index.html Edgar Link pending
0001213900-23-086133.txt Edgar Link pending
0001213900-23-086133-xbrl.zip Edgar Link pending
f10q0923ex31-1_hoththerap.htm Edgar Link pending
f10q0923ex31-2_hoththerap.htm Edgar Link pending
f10q0923ex32-1_hoththerap.htm Edgar Link pending
f10q0923ex32-2_hoththerap.htm Edgar Link pending
f10q0923_hoththerap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hoth-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hoth-20230930_cal.xml Edgar Link unprocessable
hoth-20230930_lab.xml Edgar Link unprocessable
hoth-20230930_def.xml Edgar Link unprocessable
hoth-20230930_pre.xml Edgar Link unprocessable
f10q0923_hoththerap_htm.xml Edgar Link completed